Table 3 Novel therapeutics in Polycythemia Vera
From: Erythropoiesis: insights into pathophysiology and treatments in 2017
| Company | Drug | Mechanism | Eligibility | Route | Clintrials.gov | Status |
|---|---|---|---|---|---|---|
| Small molecules targets | ||||||
| Incyte Coproration Novartis | Jak 1/2 inhibitor (ruxolitinib) vs BAT | Cytoreduction | - age ≥ 18 years | Oral | NCT01243944 |
Active, not recruiting - Phase 3 |
| Incyte | Jak 1/2 inhibitor (ruxolitinib) vs HU | Cytoreduction | - age ≥ 18 years | Oral | NCT01632904 |
Completed - Phase 3 |
| AOP Orphan Pharmaceuticals AG | Pegylated interferon alpha-2b (AOP2014) vs HU | Cytoreduction | - age ≥ 18 years | subcutaneously | NCT01949805 |
Completed - Phase 3 |
| Roskilde University Hospital, | Vorinostat | Cytoreduction | - age ≥ 18 years | Oral | – |
Completed - Phase 2 |
| Italframaco | Givinostat vs HU | Cytoreduction | - age ≥ 18 years | Oral | NCT00928707 |
Completed - Phase 2 |